=Bluebirdbio (BLUE) reported earnings on Wed 1 Nov 2017 (b/o)

Bluebirdbio misses by $0.02, misses on revs 

• Reports Q3 (Sep) loss of $1.73 per share, $0.02 worse than the Capital IQ Consensus of ($1.71); revenues rose 397.4% year/year to $7.71 mln vs the $8.47 mln Capital IQ Consensus.
• Today, bluebird bio announced that the company will present clinical and pre-clinical data in 11 abstracts spanning the company's research and development portfolio.
• Cash, cash equivalents and marketable securities as of September 30, 2017 were $1.1 billion, compared to $884.8 million as of December 31, 2016, an increase of $257.8 million.
• "Coming into ASH, we have an early, but promising, indication that the changes we made in the HGB-206 study have improved engraftment and that mobilization and collection of stem cells using plerixafor may be a safe and viable option for patients with severe sickle cell disease. At ASH, we look forward to sharing additional data across our clinical programs as well as preclinical data that supports our future pipeline."